Pinebridge Investments L.P. Buys 2,805 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Pinebridge Investments L.P. raised its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYFree Report) by 38.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 10,181 shares of the biopharmaceutical company’s stock after buying an additional 2,805 shares during the period. Pinebridge Investments L.P.’s holdings in Alnylam Pharmaceuticals were worth $1,949,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of ALNY. Quent Capital LLC lifted its stake in Alnylam Pharmaceuticals by 246.0% in the 4th quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 123 shares in the last quarter. Anchor Investment Management LLC purchased a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $38,000. Robeco Institutional Asset Management B.V. grew its position in Alnylam Pharmaceuticals by 155.7% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 12,513 shares during the last quarter. GAMMA Investing LLC purchased a new position in Alnylam Pharmaceuticals in the 4th quarter worth about $52,000. Finally, Lindbrook Capital LLC raised its stake in shares of Alnylam Pharmaceuticals by 37.2% during the fourth quarter. Lindbrook Capital LLC now owns 369 shares of the biopharmaceutical company’s stock valued at $71,000 after acquiring an additional 100 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on ALNY shares. Cantor Fitzgerald restated a “neutral” rating and issued a $165.00 price target on shares of Alnylam Pharmaceuticals in a report on Tuesday, February 20th. Wolfe Research assumed coverage on Alnylam Pharmaceuticals in a report on Thursday, February 15th. They issued a “peer perform” rating on the stock. Morgan Stanley decreased their price objective on Alnylam Pharmaceuticals from $184.00 to $176.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 13th. BMO Capital Markets reiterated an “outperform” rating and issued a $234.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 27th. Finally, Wells Fargo & Company lowered their price target on shares of Alnylam Pharmaceuticals from $171.00 to $161.00 and set an “equal weight” rating on the stock in a report on Friday, February 16th. Seven research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $216.19.

Check Out Our Latest Research Report on Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock opened at $152.78 on Friday. The business has a fifty day moving average of $149.44 and a 200 day moving average of $162.91. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $218.88. The firm has a market capitalization of $19.33 billion, a price-to-earnings ratio of -57.01 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.23. The firm had revenue of $494.33 million during the quarter, compared to analysts’ expectations of $428.01 million. During the same quarter in the previous year, the business earned ($1.40) earnings per share. The company’s revenue for the quarter was up 54.8% compared to the same quarter last year. As a group, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -3.77 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Amy W. Schulman sold 21,700 shares of the company’s stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total value of $3,224,620.00. Following the sale, the director now directly owns 8,436 shares of the company’s stock, valued at approximately $1,253,589.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Company Profile

(Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Recommended Stories

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYFree Report).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.